Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
2022 · Muscle & Nerve · 24 citations
https://doi.org/10.1002/mus.27768
A
Alexander Kalin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
8
Papers
65
Citations
3
h-index
3
i10-index
Alexander Kalin is an academic researcher from Mitsubishi Corporation (United States). The author has contributed to research in topics: Amyotrophic Lateral Sclerosis Research & Parkinson's Disease Mechanisms and Treatments & Neurogenetic and Muscular Disorders Research. The author has an h-index of 3, co-authored 7 publications.
Papers by this author
worksAnalysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch
2022 · Drugs in R&D · 17 citations
https://doi.org/10.1007/s40268-022-00391-6
Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment
2025 · Muscle & Nerve · 3 citations
https://doi.org/10.1002/mus.28451
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat